海王生物 (000078)
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD
K-Line Chart
No K-line data available
Company NameShenzhen Neptunus Bioengineering Co., Ltd.
Listing Date1998-12-18
Issue Price5.36RMB
Registered Capital263112.325710k RMB
Legal RepresentativeZhang Feng
Registered Address24th Floor, Neptunus Galaxy Technology Building, No. 1 Keji Zhong San Road, Science and Technology Park, Nanshan District, Shenzhen, Guangdong Province
IndustryPharmaceutical Commerce
Main BusinessPharmaceutical manufacturing and pharmaceutical commercial distribution.
Company ProfileShenzhen Neptunus Bioengineering Co., Ltd. focuses on the pharmaceutical and healthcare industry, adhering to innovation as the fundamental driving force for corporate development. It has become a large backbone enterprise in China's pharmaceutical and healthcare sector with a relatively complete industry chain, strong independent innovation capabilities, and outstanding business model innovation capabilities. Its main businesses cover the entire industry chain, including R&D and manufacturing of pharmaceutical and healthcare products, pharmaceutical logistics, chain drugstores, internet services, and comprehensive healthcare. The company possesses leading domestic independent innovation capabilities for pharmaceutical and healthcare products and a comprehensive R&D system. It operates national-level R&D platforms such as the "National Technology Center," "National High-Tech R&D Program Achievement Industrialization Base," and a Postdoctoral Research Station. It is one of the few pharmaceutical enterprises in China with the capability to develop Class I new drugs and has achieved significant breakthroughs in this field.
Stock Details
1. Key Indicators
- Total Shares(W): 263112.33
- Circulating A-Shares(W): 262644.11
- Earnings Per Share(RMB): 0.0098
- Net Assets Per Share(RMB): 0.6926
- Operating Revenue(W RMB): 2151292.02
- Total Profit(W RMB): 16790.06
- Net Profit Attributable to Parent(W RMB): 2570.30
- Net Profit Growth Rate(%): -44.39
- Weighted Return on Equity(%): 1.4200
- Operating Cash Flow Per Share(RMB): 0.0150
- Undistributed Profit Per Share(RMB): -1.1016
- Capital Reserve Per Share(RMB): 0.7973
2. Main Business
The main business covers:
- Pharmaceutical manufacturing and distribution
- Health products and food sales
- Medical equipment sales
3. Company Basic Information
- Company Name: Shenzhen Neptunus Bioengineering Co., Ltd.
- Listing Date: 1998-12-18
- Industry: Medicine & Healthcare - Pharmaceutical Commerce (CSRC Industry: Wholesale)
- Address: 24F, Neptunus Galaxy Technology Building, No.1 Keji 3rd Road, Nanshan District, Shenzhen, Guangdong, China
- Website: www.neptunusbio.com
- Company Profile: The company's predecessor was Shenzhen Shekou Neptunus Bioengineering Co., Ltd. It was later restructured and established as a joint-stock company by Shenzhen Neptunus Bioengineering Co., Ltd., officially registered on September 1, 1998. Shenzhen Neptunus Bioengineering Co., Ltd. converted its invested assets into 57.3 million legal person shares. On August 7, 1998, it issued 17.19 million public shares, bringing the total share capital at the time of listing to 76.4 million shares. Among them, 1.91 million internal employee shares, using the quota, were listed and traded together with the 17.19 million public shares on the Shenzhen Stock Exchange on December 18, 1998.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Neptunus Group Co., Ltd. | General Legal Person | 121644.51 | 46.32 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 1348.84 | 0.51 |
| 3 | <值> | <值> | <值> | <值> |
| 4 | <值> | <值> | <值> | <值> |
| 5 | <值> | <值> | <值> | <值> |
| 6 | <值> | <值> | <值> | <值> |
| 7 | <值> | <值> | <值> | <值> |
| 8 | <值> | <值> | <值> | <值> |
| 9 | <值> | <值> | <值> | <值> |
| 10 | <值> | <值> | <值> | <值> |
5. Concept Sectors
- Biological Vaccine
- Guangdong-Hong Kong-Macao Greater Bay Area
- Vitamins
- Generic Drugs
- Mask Protection
- Cold Chain Logistics
- Innovative Drugs
- Margin Trading & Securities Lending
- Non-Recurring Loss
- Consecutive Losses
- Equity Transfer
- Recent Weakness
- High Pledged Shares
- Restructuring Plan
- High Debt Ratio
- Low Safety Score
- High Accounts Receivable
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information